• Dasatinib Monohydrate (BMS-354825): Precision ABL Inhibition

  2026-07-15

  Dasatinib Monohydrate is a potent, multitargeted ABL kinase inhibitor with sub-nanomolar activity, validated for chronic myeloid leukemia research. It overcomes imatinib-resistant BCR-ABL mutations and is FDA-approved for CML and Ph-positive ALL. APExBIO supplies rigorously characterized Dasatinib Monohydrate (SKU B5954) for reproducible kinase pathway interrogation.

• BCL-2 Inhibition Potentiates mTORC1/2 Blockade in PIK3CA-Mut

  2026-07-14

  This study demonstrates that BCL-2 family inhibition can significantly enhance the efficacy of mTORC1/2 inhibitors in PIK3CA-mutant colorectal cancer. By integrating high-throughput organoid screening and in vivo models, the authors provide a mechanistic rationale for dual pathway targeting, revealing BCL-xL as a key determinant of therapeutic response.

• Foretinib (GSK1363089): Protocol Innovations in Cancer Resea

  2026-07-14

  Foretinib (GSK1363089) stands out as a multikinase inhibitor, enabling precise tumor cell growth inhibition and advanced metastasis modeling. This article details optimized workflows, protocol parameters, and troubleshooting strategies that empower researchers to achieve reproducible, high-impact results in translational oncology.

• Dasatinib Monohydrate: Enhancing CML Research and Assay Prec

  2026-07-13

  Dasatinib Monohydrate (BMS-354825) is a multitargeted kinase inhibitor that delivers robust efficacy in chronic myeloid leukemia research, especially in models of imatinib resistance. This article details experimental workflows, practical protocol parameters, and troubleshooting insights, leveraging the latest evidence on kinase signaling and neutrophil extracellular trap modulation.

• Resiniferatoxin (RTX): Redefining Pain Intervention in Osteo

  2026-07-13

  Discover how Resiniferatoxin (RTX) delivers ultra-selective, long-lasting pain relief in osteoarthritis by targeting TRPV1 channels. This article uniquely explores RTX’s translational leap from bench to clinic and offers advanced protocol insights for researchers.

• Rotigotine hydrochloride: Reliable Solutions in PD Cell Assa

  2026-07-12

  This article addresses common laboratory challenges in dopaminergic signaling and Parkinson's disease research, demonstrating how Rotigotine hydrochloride (SKU A3777) from APExBIO delivers reproducible, data-driven solutions. Scenario-based Q&A explores protocol optimization, experimental design, and vendor reliability to help researchers achieve robust cell viability and neuroprotection results.

• Redefining In Vitro Drug Response Metrics in Cancer Research

  2026-07-10

  Schwartz's dissertation challenges the routine conflation of proliferation arrest and cell death in in vitro cancer drug assays. By dissecting these distinct drug-induced effects and proposing refined metrics, this work offers a more accurate framework for evaluating anti-cancer agents and optimizing translational research.

• GLT-1 Upregulation Mitigates TBI via CB1-CREB Pathway Inhibi

  2026-07-09

  This study elucidates how upregulation of GLT-1 attenuates neuronal apoptosis and cognitive dysfunction after traumatic brain injury (TBI) in mice by inhibiting the CB1-CREB signaling pathway. The findings provide mechanistic insight into the interplay between endocannabinoid signaling and glutamate transporter regulation, offering a potential therapeutic avenue for neuroprotection in TBI.

• Ruxolitinib Enhances Immune Modulation in Murine Sarcoma Mod

  2026-07-09

  This study demonstrates that combining Ruxolitinib with oncolytic HSV therapy significantly reshapes the tumor immune microenvironment in murine sarcoma, increasing CD4+ T cell activity and germinal center B cell populations. The use of a 46-color spectral cytometry panel enabled an unprecedented, high-dimensional immune profiling, providing new insights for immunotherapy development in resistant soft-tissue sarcomas.

• Cefepime (BMY-28142) for Robust CNS Infection Research Workf

  2026-07-08

  This article addresses real laboratory challenges in central nervous system infection research, focusing on the use of Cefepime (BMY-28142), SKU BA1013. By exploring scenario-driven Q&As, we demonstrate how this APExBIO product ensures experimental reproducibility and robust antimicrobial profiling across Gram-positive and Gram-negative bacteria.

• Hydrocortisone: Strategic Leverage for Translational Immune

  2026-07-08

  Explore how hydrocortisone, a key endogenous glucocorticoid hormone, provides translational researchers with mechanistic insights and strategic advantages in modeling inflammation, stress responses, and neuroprotection. This article bridges foundational receptor biology, contemporary evidence, and workflow optimization—empowering teams to move confidently from bench to bedside with APExBIO’s rigorously validated hydrocortisone.

• Synergistic Antibacterial Action of Copper and Hexetidine In

  2026-07-07

  This study rigorously demonstrates that copper and hexetidine, when combined, exhibit a synergistic antibacterial effect against Streptococcus sobrinus and Streptococcus sanguis in vitro. These findings have immediate methodological implications for optimizing antibacterial assays and inform broader strategies in resistance research.

• SNS-032 (BMS-387032): Selective CDK Inhibitor for Cancer & V

  2026-07-07

  SNS-032 (BMS-387032) is a potent, selective cyclin-dependent kinase inhibitor that disrupts cell cycle regulation and transcriptional control. It demonstrates nanomolar inhibition of CDK2, CDK7, and CDK9, with validated efficacy in apoptosis induction in cancer cells and host-targeted antiviral research. Its mechanistic clarity and robust benchmarks position SNS-032 as a versatile tool in translational oncology and virology.

• Bleomycin Sulfate: Protocols for DNA Damage & Fibrosis Model

  2026-07-06

  Bleomycin Sulfate is a rigorously characterized reagent for modeling chemotherapy-induced DNA damage and pulmonary fibrosis in both cellular and animal research systems. Its proven ability to induce DNA strand breaks and fibrotic changes makes it a standard choice for mechanistic studies of cancer and lung injury. Use is not recommended for applications outside validated oncology and fibrosis research workflows.

• Super-Enhancer LINC01977 Drives LUAD via TGF-β/SMAD3 Pathway

  2026-07-06

  Zhang et al. uncovered that super-enhancer hijacking of the lncRNA LINC01977 drives early-stage lung adenocarcinoma (LUAD) progression by activating the canonical TGF-β/SMAD3 pathway. Their integrated genomic and functional studies highlight LINC01977 as a promising therapeutic target in LUAD, especially for cases with high TGF-β microenvironment and tumor-associated macrophage infiltration.

15338 records 1/1023 page Next 12345 下5页 Last page